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transitions from one state to another within discrete time
frames (6 months). The states were: non-user; has sam-
pled (has tried); non-dependent user; ex-user; dependent-
not treated; dependent-treated; abstinent; death. The av-
erage quantity of heroin demanded was determined at the
cohort level, based on published price and income elastic-
ities. Scenario-analyses showed the impact of variations
in different parameters and the effects of different policy
measures on the results. Using a bottom-up approach, the
results were then aggregated to a population level.
RESULTS: Calculating the 20-year demand for heroin on
a cohort level generated an average demand between
5.96g to 20.45g per European citizen, depending on dif-
ferent variables in the model. Sub-analyses showed that a
50% increase in the price level of heroin could have a
negative impact of 72% on total heroin demand. A de-
crease in sampling of 50% generated an almost equal im-
pact on total heroin demand. Analyzing the impact of
substitution treatment indicated that easier access to
treatment and a longer follow-up after completing treat-
ment would have a greater impact than the success of
treatment itself in achieving abstinence.
CONCLUSIONS: This is the first macro-economic model
designed for policy makers to assess the impact of mea-
sures to control problematic drug use. Measures aimed at
preventing a first heroin dose and controlling the price of
heroin seem to be worth focussing on.
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OBJECTIVE:
 
 To develop criteria for testing the validity
of indicators of prescribing cost, efficiency or quality.
 
METHODS:
 
 Our methodology was based on techniques
used to validate psychological tests. Face validity was
used to test the construct of the prescribing indicator (i.e.
what is it trying to measure?). Two tests of external va-
lidity were used to relate the performance of each indica-
tor to other measures of the same construct (concurrent
validity and predictive validity). In addition we used a
published method to test the robustness of ranking of
General Practices by each prescribing indicator. We ob-
tained data for all 78 General Practices in Tayside for the
years 1993-97.
RESULTS: We identified five prescribing indicators that
had been previously tested for face validity in a two-stage
Delphi consultation study. These were: 1) the ratio of
bendrofluazide 2.5mg to total bendrofluazide items; 2)
the ratio of generic items to all items; 3) the ratio of tri-
methoprim to trimethoprim/sulphamethoxazole; 4) the
ratio of antibiotics from the primary-care formulary to
all antibiotics; and, 5) the ratio of maintenance dose of
proton pump inhibitors to all PPI items. Crude ranking of
general practices compared well with the results of the
more robust rankings generated by the Marshall and
Spiegelhalter ranking. There were significant improve-
ments in the achievement of all five indicators by Tayside
practices from 1993 to 1997, and ranking of each prac-
tice was robust over time. However, there was no rela-
tionship between an individual practice’s ranking by dif-
ferent indicators.
CONCLUSIONS: Differences between practices are sta-
tistically robust and practices have shown significant
improvements in all indicators over time. However, the
absence of concurrent validity between indicators casts
doubt on their use as measures of general prescribing
quality.
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OBJECTIVES:
 
 We use the Chronic Disease Score meth-
odology to estimate the prevalence of a number of
chronic conditions in the Republic of Ireland from rou-
tinely available prescribing data, which we then compare
with epidemiological estimates.
METHODS: Using automated outpatient pharmacy data,
measures of chronic disease severity called Chronic Dis-
ease Scores were constructed. We use these to measure
disease prevalence. Since many drugs have multiple indi-
cations, incidental users and the chronically ill must be
distinguished. Any person receiving four or more pre-
scriptions within a 12-month period for a chronic disease
category is identified as suffering from that chronic dis-
ease. Prevalence estimates are compared with estimates
for these conditions based on a review of the epidemiol-
ogy literature. Data refer to the General Medical Services
(GMS) scheme in Ireland. The GMS provides free pri-
mary care to those on low income and to other hardship
cases, covering approximately 31% of the Irish popula-
tion. Data on drugs prescribed to all individuals on the
GMS scheme in four health board areas were collected
for the period from September 1999 to August 2000, rep-
resenting a total of 415,271 people or approximately
37% of the GMS population.
RESULTS: Estimates of prevalence based on the Chronic
Disease Score are similar to epidemiological estimates.
This is especially true for conditions such as diabetes, ep-
ilepsy and asthma, and less so for depression and other
mental illness, where under-diagnosis is commonplace.
CONCLUSIONS: The results suggest that prescribing data
is a rich source of information on morbidity in the com-
munity. It is locally sensitive, timely and cheap to collect.
As long as certain caveats are applied, this type of infor-
mation has many uses in the surveillance of the public’s
health.
